

(Continued)

Previous pathologies	Steatohepatitis	Liver cirrhosis
<b>Dyspnea</b>	13 (52%)	12 (46%)
<b>Pneumonia</b>	5 (20%)	8 (32%)
<b>Asthenia</b>	6 (24%)	6 (24%)
<b>Fever</b>	2 (8%)	13 (52%)
<b>Headache</b>	3 (12%)	8 (31%)
<b>Anosmia</b>	1 (4%)	1 (4%)
<b>Shivers</b>	1 (4%)	1 (4%)
<b>Arthralgia</b>	3 (12%)	2 (8%)
<b>Diarrhea</b>	1 (4%)	2 (8%)

<https://doi.org/10.1016/j.aohep.2022.100837>

**Pilot study: management with pentoxifylline in patients with chronic liver disease and COVID-19**

MA Jiménez-Luévano, AE Jiménez-Partida, MA Jiménez-Partida, A Bravo-Cuellar, Y Cortes-Aguilar

Regional Hospital “Dr. Valentín Gómez Farías”. Gastroenterology Service. ISSSTE. Mexico

**Introduction and Objectives:** This study aimed to improve the response to adjuvant treatment with pentoxifylline in patients with SARS-CoV-2 and previous chronic liver disease.

**Materials and Methods:** In the ISSSTE hospital of Zapopan for eight months, 51 patients with moderate to severe SARS-CoV-2 and chronic liver disease, 26 with cirrhosis and 25 with steatohepatitis were evaluated, with prior informed consent and endorsed by the ethics committee. They were administered pentoxifylline 400 mg for 28 days, in addition to supportive measures such as paracetamol 750 mg, celecoxib 100 mg, or anticoagulants (enoxaparin) in patients with D-dimer > 600 mg/dL and supplemental oxygen in patients with saturation < 90. Clinical, laboratory and mortality variables were analyzed. The trial was approved by the research ethics committee, and informed consent was obtained.

**Results:** They were patients with Covid-19 plus cirrhosis and steatohepatitis. They survived 100%, after 28 days of driving, in addition to avoiding admission to intensive care.

**Discussion:** Pentoxifylline is a methylxanthine with antioxidant, hemorheological, anti-inflammatory and immunomodulatory properties since it inhibits NF-KB (via JAK/STAT and 1KB), pro-inflammatory cytokines, phosphodiesterase, in addition to stimulating anti-inflammatory cytokines, interferon-gamma, growth factors, TGF beta and granulocyte growth factor. Also, antiviral, as in Japanese encephalitis virus, vaccine virus, Rotavirus, HPV, respiratory syncytial virus, HIV, HCV, etc.

**Conclusions:** This viremia is severe in vulnerable groups, particularly liver diseases. It is inferred that Pentoxifylline may be alternative management, as manifested in this group of patients who managed to survive. So, we suggest multicenter and randomized studies to know their real benefit.

**Funding:** The resources used in this study were from the hospital without any additional financing

**Declaration of interest:** The authors declare no potential conflicts of interest.

**Table 1.** Demographic, biochemical and symptomatology characteristics of the two groups

Previous pathologies	Steatohepatitis	Liver cirrhosis
<b>Age</b>	55.64	60.84
<b>Gender</b>	72% women - 28% men	42% women – 58% men
<b>BMI</b>	30.76	27.84
<b>Comorbidities</b>		
<b>Overweight / obesity</b>	100%	100%

(continued)

(Continued)

Previous pathologies	Steatohepatitis	Liver cirrhosis
<b>DM 2</b>	31%	20%
<b>Alcoholism</b>	0%	27%
<b>Autoimmune disease</b>	0%	4%
<b>Laboratory</b>		
<b>AST</b>	42.24	56.76
<b>ALT</b>	50.25	69.90
<b>DHL</b>	308.2	315.6
<b>Platelets</b>	170	100.38
<b>Ferritin</b>	496.24	592.5
<b>D-dimer</b>	530.54	1,064
<b>Lymphocytes</b>	35.2	29.96
<b>ESR</b>	32.32	30.06
<b>PCR</b>	49	47.03
<b>Oxygen saturation</b>	85.24	85.69
<b>Clinic:</b>		
<b>Cough</b>	16 (64%)	14 (54%)
<b>Dyspnea</b>	13 (52%)	12 (46%)
<b>Pneumonia</b>	5 (20%)	8 (32%)
<b>Asthenia</b>	6 (24%)	6 (24%)
<b>Fever</b>	2 (8%)	13 (52%)
<b>Headache</b>	3 (12%)	8 (31%)
<b>Anosmia</b>	1 (4%)	1 (4%)
<b>Shivers</b>	1 (4%)	1 (4%)
<b>Arthralgia</b>	3 (12%)	2 (8%)
<b>Diarrhea</b>	1 (4%)	2 (8%)

<https://doi.org/10.1016/j.aohep.2022.100838>

**To present a clinical case of a 52-year-old female patient with a diagnosis of pyogenic liver abscesses**

RJ Ortega-García

General Hospital “Dr. Aurelio Valdivieso”. Secretaría de Salud. Oaxaca. México

**Introduction and Objectives:** a case of pyogenic abscesses is presented

**Case Summary:** 52 years old woman begins her condition with pain in the right hypochondrium, with an intensity 3/10, which increases with inspiration. She also refers to pain in the epigastrium, of postprandial onset, exacerbated by diet. Upon examination, she found the patient to be calm, cooperative, and well-oriented in her three neurological spheres, norm reflexes pupils, and oral mucosa well hydrated. Cylindrical neck, no lymph nodes, cardiopulmonary without compromise. Globose abdomen at the expense of panniculus adiposus, peristalsis present, pain on superficial and deep palpation in the right hypochondrium. Whole limbs.

**Results:** Treatment was started with metronidazole 500mg IV every 8 hours and ceftriaxone 1g IV every 12 hours for 28 days. The patient shows decreased pain in the right hypochondrium and clinical improvement, so it is decided to discharge her at the end of the month.

**Discussion:** Starting treatment in a timely manner in the patient reduces the number of complications such as the acute abdomen, occlusion of the hepatic veins, and occlusion of the inferior vena cava.

**Conclusion:** Starting early antibiotic therapy allows us to improve the prognosis of our patients with pyogenic liver abscesses, reducing morbidity and mortality.

**Funding:** The resources used in this study were from the hospital without any additional financing

**Declaration of interest:** The authors declare no potential conflicts of interest

<https://doi.org/10.1016/j.aohep.2022.100839>